For Merck, the drug that concerns investors is Keytruda. The blockbuster cancer drug faces patent expiration in 2028.
Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback